oalib

Publish in OALib Journal

ISSN: 2333-9721

APC: Only $99

Submit

Any time

2019 ( 88 )

2018 ( 522 )

2017 ( 533 )

2016 ( 770 )

Custom range...

Search Results: 1 - 10 of 325193 matches for " Mousa S. Marouf "
All listed articles are free for downloading (OA Articles)
Page 1 /325193
Display every page Item
Asymptotic equivalence and summability
Mousa S. Marouf
International Journal of Mathematics and Mathematical Sciences , 1993, DOI: 10.1155/s0161171293000948
Abstract: This paper is a study of the relatioship. between the asymptotic equivalence of two sequences (limnxn/yn=1) and three variatious of this equivalence for a sequence-to-sequence transformation A, the three variations are give by the ratios RmAx/RmAy. SmAx/SmAy, And mAx/ mAy, where RmAz:= ¢ ‘n ¢ ‰ ¥m|(Az)n|, SmAz:= ¢ ‘n ¢ ‰ ¤m|(Az)n|, and mAz:=supn ¢ ‰ ¥m|(Az)n|.
Characterization of the Crystal Structure of Sesame Seed Cake Burned by Nd: YAG Laser  [PDF]
Muna A. Pn Gawbah, Abdelrahman A. Elbadawi, Yousef A. Alsabah, Mohammed U. Orsod, Ali A. S. Marouf
Journal of Materials Science and Chemical Engineering (MSCE) , 2018, DOI: 10.4236/msce.2018.64013
Abstract: This paper reports obtaining of useful and high-value materials from sesame seed cake (SSC). For this purpose, SSC sample was burned for 30 s using Nd: YAG laser with output power 60 W. The products of this process and non-burned SSC were characterized by X-ray diffractometer (XRD), energy dispersive x-ray (EDX) and Fourier transform infrared (FTIR) so as to investigate its crystal structure and chemical components. XRD results of the SSC before burning process showed amorphous silica, rhombohedral phase of carbon, monoclinic phase of aluminum chloride, the hexagonal phase of moissanite-4H, (yellow, black) and hexagonal phase of graphite-2H, C (black). While the results of the burned SSC sample showed that the burning process using the power of Nd: YAG laser cased in appearing of crystalline hexagonal phase for silica and Carbon Nitride and converting the rhombohedral phase of Carbon into hexagonal phase. FTIR showed a number of absorbance peaks assigned to silica.
Radiative transfer in closely packed realistic regoliths
S. Vahidinia,J. Cuzzi,B. Draine,E. Marouf
Atti della Accademia Peloritana dei Pericolanti : Classe di Scienze Fisiche, Matematiche e Naturali , 2011, DOI: 10.1478/c1v89s1p089
Abstract: We have developed a regolith radiative transfer model (RRT) based on a first-principles approach to regolith modeling that is essential for near-to-far infrared observations of grainy surfaces, and is readily configured to answer fundamental questions about popular models with which all remote observations of all airless solar system bodies with granular surfaces are currently interpreted. Our model accounts for wavelength-size regolith particles which are closely packed and can be heterogeneous in composition and arbitrarily shaped. Here we present preliminary results showing the role of porosity on layer reflectivity.
Neural-Network-Based Fault Location Estimator for Short Medium Voltage Underground Cable
Marouf Pirouti
International Journal of Electrical and Power Engineering , 2012,
Abstract: A new application of neural network approach to estimate fault location of short Medium voltage underground cables is demonstrated in this study. Different faults on a protected cable should be classified and location should be estimated. This study presents, the use of neural networks as a pattern classifier algorithm to perform these tasks. The proposed algorithm has a good performance to variation of different parameters such as fault type, fault resistance and fault inception angle. Studies show that the proposed technique is able to offer acceptable accuracy in estimation of fault location.
Polycystic ovary syndrome and its impact on women’s quality of life: More than just an endocrine disorder
Christine Brady, Shaymaa S Mousa, Shaker A Mousa
Drug, Healthcare and Patient Safety , 2009, DOI: http://dx.doi.org/10.2147/DHPS.S4388
Abstract: lycystic ovary syndrome and its impact on women’s quality of life: More than just an endocrine disorder Review (5395) Total Article Views Authors: Christine Brady, Shaymaa S Mousa, Shaker A Mousa Published Date February 2009 Volume 2009:1 Pages 9 - 15 DOI: http://dx.doi.org/10.2147/DHPS.S4388 Christine Brady, Shaymaa S Mousa, Shaker A Mousa The Pharmaceutical Research Institute, Albany College of Pharmacy and Health Sciences, Albany, NY, USA Abstract: In the past, polycystic ovary syndrome has been looked at primarily as an endocrine disorder. Studies now show that polycystic ovary syndrome is a metabolic, hormonal, and psychosocial disorder that impacts a patient’s quality of life. It is extremely important to holistically treat these patients early on to help them deal with the emotional stress that is often overlooked with polycystic ovary syndrome. Early diagnosis and long term management can help control polycystic ovary syndrome so that women can still live a healthy active life and avoid long-term complications such as metabolic syndrome and cardiovascular diseases.
Pharmacogenomics in cardiovascular disorders: Steps in approaching personalized medicine in cardiovascular medicine
Christopher Barone, Shaymaa S Mousa, Shaker A Mousa
Pharmacogenomics and Personalized Medicine , 2009, DOI: http://dx.doi.org/10.2147/PGPM.S5805
Abstract: rmacogenomics in cardiovascular disorders: Steps in approaching personalized medicine in cardiovascular medicine Review (7141) Total Article Views Authors: Christopher Barone, Shaymaa S Mousa, Shaker A Mousa Published Date September 2009 Volume 2009:2 Pages 59 - 67 DOI: http://dx.doi.org/10.2147/PGPM.S5805 Christopher Barone, Shaymaa S Mousa, Shaker A Mousa The Pharmaceutical Research Institute, Albany College of Pharmacy and Health Sciences, Albany, NY, USA Abstract: Some of the most commonly prescribed medications are those for cardiovascular maladies. The beneficial effects of these medications have been well documented. However, there can be substantial variation in response to these medications among patients, which may be due to genetic variation. For this reason pharmacogenomic studies are emerging across all aspects of cardiovascular medicine. The goal of pharmacogenomics is to tailor treatment to an individual’s genetic makeup in order to improve the benefit-to-risk ratio. This review examines the potential pharmacogenomic parameters which may lead to a future of personalized medicine. For example, it has been found that patients with CYP2C9 and VKORC1 gene variations have a different response to warfarin. Other studies looking at β-blockers, ACE inhibitors, ARBs, diuretics and statins have shown some results linking genetic variations to pharmacologic response. However these studies have not impacted clinical use yet, unlike warfarin findings, as the small retrospective studies need to be followed up by larger prospective studies for definitive results.
Pharmacogenomics in type II diabetes mellitus management: Steps toward personalized medicine
Peter Avery, Shaymaa S Mousa, Shaker A Mousa
Pharmacogenomics and Personalized Medicine , 2009, DOI: http://dx.doi.org/10.2147/PGPM.S5806
Abstract: rmacogenomics in type II diabetes mellitus management: Steps toward personalized medicine Review (9044) Total Article Views Authors: Peter Avery, Shaymaa S Mousa, Shaker A Mousa Published Date September 2009 Volume 2009:2 Pages 79 - 91 DOI: http://dx.doi.org/10.2147/PGPM.S5806 Peter Avery, Shaymaa S Mousa, Shaker A Mousa The Pharmaceutical Research Institute, Albany College of Pharmacy and Health Sciences, Albany, NY, USA Abstract: Advances in genotype technology in the last decade have put the pharmacogenomics revolution at the forefront of future medicine in clinical practice. Discovery of novel gene variations in drug transporters, drug targets, effector proteins and metabolizing enzymes in the form of single-nucleotide polymorphisms (SNPs) continue to provide insight into the biological phenomena that govern drug efficacy and toxicity. To date, novel gene discoveries extracted from genome-wide association scans and candidate gene studies in at least four antidiabetic drug classes have helped illuminate possible causes of interindividual variability in response. Inadequate protocol guidelines for pharmacogenomics studies often leads to poorly designed studies, making it hard to formulate a definitive conclusion regarding the clinical relevance of the information at hand. These issues, along with the ethical, social, political, legislative, technological, and economic challenges associated with pharmacogenomics have only delayed its entry to mainstream clinical practice. On the other hand, these issues are being actively pursued and rapid progress is being made in each area which assures the possibility of gaining widespread acceptance in clinical practice.
Pharmacogenomics in type II diabetes mellitus management: Steps toward personalized medicine
Peter Avery,Shaymaa S Mousa,Shaker A Mousa
Pharmacogenomics and Personalized Medicine , 2009,
Abstract: Peter Avery, Shaymaa S Mousa, Shaker A MousaThe Pharmaceutical Research Institute, Albany College of Pharmacy and Health Sciences, Albany, NY, USAAbstract: Advances in genotype technology in the last decade have put the pharmacogenomics revolution at the forefront of future medicine in clinical practice. Discovery of novel gene variations in drug transporters, drug targets, effector proteins and metabolizing enzymes in the form of single-nucleotide polymorphisms (SNPs) continue to provide insight into the biological phenomena that govern drug efficacy and toxicity. To date, novel gene discoveries extracted from genome-wide association scans and candidate gene studies in at least four antidiabetic drug classes have helped illuminate possible causes of interindividual variability in response. Inadequate protocol guidelines for pharmacogenomics studies often leads to poorly designed studies, making it hard to formulate a definitive conclusion regarding the clinical relevance of the information at hand. These issues, along with the ethical, social, political, legislative, technological, and economic challenges associated with pharmacogenomics have only delayed its entry to mainstream clinical practice. On the other hand, these issues are being actively pursued and rapid progress is being made in each area which assures the possibility of gaining widespread acceptance in clinical practice.Keywords: pharmacogenomics, genetics, pharmacokinetics, pharmacodynamics, personalized medicine, type 2 diabetes, pharmacotherapy, antidiabetic drugs, efficacy, and safety
Pharmacogenomics in cardiovascular disorders: Steps in approaching personalized medicine in cardiovascular medicine
Christopher Barone,Shaymaa S Mousa,Shaker A Mousa
Pharmacogenomics and Personalized Medicine , 2009,
Abstract: Christopher Barone, Shaymaa S Mousa, Shaker A MousaThe Pharmaceutical Research Institute, Albany College of Pharmacy and Health Sciences, Albany, NY, USAAbstract: Some of the most commonly prescribed medications are those for cardiovascular maladies. The beneficial effects of these medications have been well documented. However, there can be substantial variation in response to these medications among patients, which may be due to genetic variation. For this reason pharmacogenomic studies are emerging across all aspects of cardiovascular medicine. The goal of pharmacogenomics is to tailor treatment to an individual’s genetic makeup in order to improve the benefit-to-risk ratio. This review examines the potential pharmacogenomic parameters which may lead to a future of personalized medicine. For example, it has been found that patients with CYP2C9 and VKORC1 gene variations have a different response to warfarin. Other studies looking at β-blockers, ACE inhibitors, ARBs, diuretics and statins have shown some results linking genetic variations to pharmacologic response. However these studies have not impacted clinical use yet, unlike warfarin findings, as the small retrospective studies need to be followed up by larger prospective studies for definitive results.Keywords: cardiovascular, pharmacogenomics, genetics, cardiovascular medicine, personalized medicine, polymorphism
Polycystic ovary syndrome and its impact on women’s quality of life: More than just an endocrine disorder
Christine Brady,Shaymaa S Mousa,Shaker A Mousa
Drug, Healthcare and Patient Safety , 2009,
Abstract: Christine Brady, Shaymaa S Mousa, Shaker A MousaThe Pharmaceutical Research Institute, Albany College of Pharmacy and Health Sciences, Albany, NY, USAAbstract: In the past, polycystic ovary syndrome has been looked at primarily as an endocrine disorder. Studies now show that polycystic ovary syndrome is a metabolic, hormonal, and psychosocial disorder that impacts a patient’s quality of life. It is extremely important to holistically treat these patients early on to help them deal with the emotional stress that is often overlooked with polycystic ovary syndrome. Early diagnosis and long term management can help control polycystic ovary syndrome so that women can still live a healthy active life and avoid long-term complications such as metabolic syndrome and cardiovascular diseases.Keywords: polycystic ovary syndrome, quality of life, sexual satisfaction, infertility, psychological distress, hirsutism, metabolic syndrome
Page 1 /325193
Display every page Item


Home
Copyright © 2008-2017 Open Access Library. All rights reserved.